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Abstract BCR-ABL oncoprotein stimulates cell proliferation
and inhibits apoptosis in chronic myeloid leukemia (CML).
For cure, imatinib is a widely used tyrosine kinase inhibitor,
but developing chemotherapeutic resistance has to be over-
come. In this study, we aimed to determine differing
genome-wide microRNA (miRNA) and messenger RNA
(mRNA) expression profiles in imatinib resistant
(K562/IMA-3 μM) and parental cells by targeting STAT5A
via small interfering RNA (siRNA) applications. After deter-
mining possible therapeutic miRNAs, we aimed to check their
effects upon cell viability and proliferation, apoptosis, and
find a possible miRNA::mRNA interaction to discover the
molecular basis of imatinib resistance. We detected that
miR-2278 and miR-1245b-3p were most significantly regulat-
ed miRNAs according to miRNome array. Upregulating miR-
2278 expression resulted in the inhibition of resistant leuke-
mic cell proliferation and induced apoptosis, whereas miR-
1245b-3p did not exhibit therapeutic results. Functional anal-
yses indicated that AKT2, STAM2, and STAT5A mRNAs
were functional targets for miR-2278 as mimic transfection
decreased their expressions both at transcriptional and trans-
lational level, thus highlighting miR-2278 as a tumor suppres-
sor. This study provides new insights in discovering the mech-
anism of imatinib resistance due to upregulating the tumor-
suppressor hsa-miR-2278 which stands for a functional ther-
apeutic approach, inhibited leukemic cell proliferation, in-
duced apoptosis, and regain of chemotherapeutic drug re-
sponse in CML therapy.
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Introduction
Chronic myeloid leukemia (CML) is a malignant myelopro-
liferative neoplasm and exhibits unique biologic character by
presence of a reciprocal chromosomal translocation of the
Abelson (ABL1) oncogene on 9th chromosome and the
breakpoint cluster region (BCR) on 22nd chromosome, as
t(9;22)(q34;q11.2) [1]. This rearrangement results in the for-
mation of a chimeric fusion oncoprotein defined as p210 kDa
BCR-ABL, whereas p185 kDa and p230 kDa proteins can
also exist in CML depending upon differences in breakpoints
[2]. This encoded BCR-ABL1 is a constitutively activated
protein tyrosine kinase caused by excess activation of some
famous signaling pathways like RAS/RAF/MAPK, PI3K-
Akt, JUN, MYC, and Janus kinase/signal transducers and ac-
tivators of transcription (JAK/STAT) [2, 3].
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As discovering the molecular basis of CML, new treatment
strategies were spread out to block BCR-ABL1’ s tyrosine
kinase activity like Bimatinib^ (Glivec®, formerly known as
CGP 57148B) as being a FDA-approved first-line therapy
and, thus, marked an era in CML as a tyrosine kinase inhibitor
(TKI) [4]. Although TKI-dependent targeted therapies are
generally well tolerated and potentially lifelong, adverse
events and gain of resistance are mostly experienced among
patients that stand for clinical problems [5]. BCR-ABL-
dependent and BCR-ABL-independent mechanisms are iden-
tified in resistance phenomenon. While overexpression of
BCR-ABL and mutations in BCR-ABL are in Bdependent
group,^ activation of signaling cascades, overexpression of
efflux transporters leading to low TKI levels in the cell, and
downregulation of influx transporters that inhibit effective
TKI shuttling within the cell are found in Bindependent
group^ [6]. Althoughmore potent second- and third-line TKIs
were generated, it was reported that imatinib-resistant patients
with a defined BCR-ABL mutation also exhibited high risk
for development of additional mutations giving also rise to
gained resistance to second- or third-line TKI therapies [7].
Thus, identifying new and alternative ways to clarify the un-
derlying resistance mechanism has unique impact for targeted
therapy. Such molecular targets are accessible from the de-
fined signaling cascades that play major roles in gained ima-
tinib resistance like STAT5A, from famous JAK/STAT path-
way. Since STAT5Ahas a deep impact uponCMLpathogenesis,
therefore, the term BSTATinib therapies^ has ascribed to it [8].
STAT5 activation is correlated with functional cellular pro-
cesses like cell proliferation, differentiation, migration, apo-
ptosis, and hematopoiesis. BCR-ABL induces a tyrosine
phosphorylation that leads to STAT5 dimerization. Dimerized
STAT5A enters the nucleus, and then binds to consensus se-
quences via their DNA binding domain that results in accel-
erated activation of downstream target genes [9].
Some earlier studies including ours have demonstrated that
STAT5A expressional inhibition has therapeutic potential as
being an effective molecular target for TKI resistance [10, 11];
thus, the strategy is to target STAT5A in various ways like
RNA interference (RNAi) technology.
RNA interference is a sequence-specific gene silencing
phenomenon in which small interfering RNAs (siRNAs) trig-
ger messenger RNA (mRNA) transcriptional and post-
transcriptional silencing, thus represents therapeutic approach
[12]. Besides this, non-coding endogenous microRNAs
(miRNAs) regulate gene expression either by causing target-
specific mRNA degradation or translational suppression.
Nowadays, miRNAs have become good therapeutic targets
since their varying expressions effect cellular fateful events
such as regulation of development, differentiation, survival,
cell aging, and cell death, whereas their abnormal expression
patterns give rise to various diseases—initially cancer and
leukemia [13]. In this study, we aimed to determine differing
genome-wide miRNA and mRNA expression profiles in ima-
tinib resistant (K562/IMA-3 μM) and parental K562 cells in-
dicating CML cell model before and after anti-STAT5A-Chl
modified siRNA applications. By this approach, we detected
new and candidate miRNAs andmRNAs that were potentially
responsible for gained imatinib resistance due to targeting
STAT5A. Therefore, new molecular targets—therapeutic
miRNAs—could be identified for regaining chemotherapeutic
drug response and accelerated cure strategies.
Once we have detected a miRNA that was significantly
differentially expressed between resistant and parental cell
due STAT5A silencing, we aimed to define the genes that
were potentially regulated by that miRNA. Secondarily, we
aimed to identify apoptotic cell death ratios due to STAT5A
silencing among cells, and also before and after miRNA trans-
fection in order to clarify whether miRNA treatment acceler-
ates leukemic cell apoptosis. At the last stage, we aimed to
determine miRNA transfection effects upon cell viability and
proliferation. Finally, as following these steps, we tried to
understand the molecular basis of gained imatinib resistance
a bit more in order to generate clinical benefit and impact, thus
put forward new therapeutic approaches.
Materials and methods
Cell lines and culturing conditions
Human chronic myelogenous leukemia cell model BK562^
was purchased from German Collection of Microorganism
and Cell Cultures company. K562 cells were maintained in
RPMI 1640 medium containing 10 % heat-inactivated fetal
bovine serum (FBS), 100 units of penicillin-streptomycin/
ml, and 1 % L-glutamine at 37 °C in humidified air containing
5 % CO2 indicated as Bsensitive cells.^ Imatinib resistant
K562 cells were developed by applying increasing doses of
imatinib (initial concentration was 50 nM) for a duration of
2 years. Following each imatinib treatment, subpopulations of
living cells were collected and the resultant cells that were
resistant to 3 μM imatinib are referred to as K562/IMA-3
cells. Cells exhibiting 95 % viability and 80 % confluence
were used in experiments.
Gene silencing by siRNA applications
Gene silencing was achieved due to HiPerFect Transfection
Reagent (Qiagen, Valencia, CA, USA) user manual in combi-
nation with chemically modified cholesterol conjugated anti-
STAT5A siRNA (Dharmacon, Chicago, IL, USA). The cho-
lesterol conjugation resided at the 5′-end of the siRNA sense-
strand that specifically binded to STAT5A mRNA and gene
silencing experiments carried out in a duration of 72 h.
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qRT-PCR assay
In order to confirm gene silencing, STAT5AmRNA transcrip-
tional expression level was determined by real-time quantita-
tive reverse transcriptase polymerase chain reaction (qRT-
PCR). For this purpose, cells were collected and total RNA
was isolated from each sample by MagNA Pure Compact
RNA Isolation kit (Roche Applied Science, Mannheim, Ger-
many). Isolated RNAs were reverse transcribed into comple-
mentary DNAs (cDNAs) by Transcriptor High Fidelity cDNA
Synthesis kit (Roche Applied Science, Mannheim, Germany),
and qRT-PCR was performed with gene-specific primers and
probes using Fast Start DNAMaster Hybridisation Probes and
Glucose-6-phosphate dehydrogenase (G6PDH) Housekeep-
ing Gene Set (Roche Applied Science, Mannheim, Germany
both) kits in LightCycler 2.0 Instrument (Roche Diagnostics,
USA). The relative STAT5A mRNA expression of each sam-
ple was calculated by dividing the mRNA copy number of
STAT5A to G6PDH mRNA copy number as the reference
gene. Gene silencing ratio was determined as comparing un-
treated control cells’ relative STAT5A expression level to
siRNA treated cells, and the suppression rate was calculated
for both K562 and K562/IMA-3 cells.
Western blot assay
Another confirmation of silencing was achieved by compar-
ing STAT5A translational expression profile in both siRNA
treated and untreated K562 and K562/IMA-3 cells. For this
purpose, cells were lysed in 0.1 ml of Complete lysis-M buffer
(Roche Applied Science, Mannheim, Germany) kit following
the instructions. The protein amounts were calculated by
Bradford method. Finally, 45 μg of each protein extract was
resolved at 8 % SDS-PAGE gel and transferred to PVDF
membranes using a dry transfer system iBlot (Invitrogen Cor-
poration, Carlsbad, CA, USA). The used primer antibody con-
centrations were both 1:1000 diluted STAT5A (06–968, Up-
state), STAM2 (#14674), AKT2 (#3063), and β-Actin
(#4967) (for both, Cell Signaling Technology, USA). Primary
antibody incubation, blotting, and secondary antibody incuba-
tion were done in accordance with iBlot® Western Detection
Kit (Invitrogen Corporation, Carlsbad, CA, USA) for chromo-
genic detection of proteins in iBlot system. The results were
evaluated with gel imaging system (Chemi Smart 2000, Vilber
Lourmat, Marne-la-Vallée, Cedex, France). Another group of
western blot experiments were done in order to determine the
interaction between miRNA and its potential target genes—
miRNA::mRNA axis of interaction.
Apoptosis assays
Apoptosis rates of anti-STAT5A-siRNA/cholesterol treated
and untreated K562 and K562/IMA-3 cells were quantified
by a photometric enzyme immunoassay by using the Cell
Death Detection ELISA Kit (Roche Applied Science, Mann-
heim, Germany) which allows for the detection of mono- and
oligonucleosomes and measures apoptotic cell death. For this
purpose, 5×104 cells were collected and kit manual was ap-
plied; finally, absorbance was measured spectrophotometri-
cally at 405 nm with an ELISA reader (Thermo, Vantaa, Fin-
land). Apoptotic cell rates were calculated after the average
values of duplicated absorbance measurements of samples
were taken and the background value was subtracted from
each of these average values. Another group of apoptosis as-
say was carried out following miRNA treatments in order to
determine their apoptotic effects upon cells.
Genome-wide microRNA array (miRNome) and mRNA
(transcriptome) array via Agilent 2100 Bioanalyzer
In order to determine differing genome-wide microRNA and
mRNA expression profiles in imatinib resistant (K562/IMA-
3 μM) and parental K562 cells, we used Agilent 2100
Bioanalyzer microarray chip system (Agilent Technologies,
Palo Alto, CA). We generated four groups of cells: parental
untreated, parental + anti-STAT5A-siRNA transfected, resis-
tant untreated, resistant + anti-STAT5A-siRNA transfected;
generating ×4 biological replicates in each group.
RNA isolation, quality, and quantity determination
Totally, 16 samples’ total RNAwas isolated via Tripure Isola-
tion Reagent Kit (Roche Applied Science, Mannheim, Ger-
many) and their quality and quantity were determined by
Agilent RNA 6000 Nano Kit (Agilent Technologies, Palo Al-
to, CA) in Agilent 2100 Bioanalyzer. All samples provided
>8.5 RNA integrity number, a clear gel image, and no DNA
contamination was observed on the histogram. We proceeded
with microarray PCR.
Genome-wide microRNA array analysis
Following quality detection steps, 100 ng RNA was reverse
transcribed by miRNA Complete Labeling and Hybridization
Kit and MicroRNA Spike-In Kit (both Agilent Technologies,
Palo Alto, CA) and then labeled with Cy3 fluorescein dye.
Next, these Cy3-labeled cDNAs were hybridized to whole
miRNome Human miRNA Microarray, Release 19.0,
8x60K(v19) by using Agilent microRNA Hybridization Kit
microarrays for 20 h. Following washing and drying steps
with Stabilizing and Drying Solution (Agilent Technologies,
Palo Alto, CA) steps, the slides were scanned by Agilent Mi-
croarray Scanner. All steps were performed according to the
manufacturer (Agilent Technologies, Palo Alto, CA) manuals.
By this approach, we analyzed 2042 mature miRNAs from
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miRBase ver:19.0 in ×4 replicates both in resistant and paren-
tal cells either anti-STAT5A-siRNA transfected or not.
Genome-wide mRNA array analysis
Following quality detection steps as indicated above, 100 ng
RNA was reverse transcribed by Low Input Quick Amp La-
beling Kit, One-color and RNA Spike-In Kit, One-Color (both
Agilent Technologies, Palo Alto, CA) and then labeled with
Cyanine 3-CTP; thus, fluorescent complementary RNA
(cRNA) was generated. Next, we used the RNeasy Mini Kit
(Qiagen, Valencia, CA) to purify the amplified cRNA samples
and they were hybridized to whole-genome Human GE
8x60K Microarray V2 by using Gene Expression Hybridiza-
tion Kit (Agilent Technologies, Palo Alto, CA) for 20 h. Fol-
lowing washing and drying steps with Gene ExpressionWash
Buffer Kit (Agilent Technologies, Palo Alto, CA) steps, the
slides were scanned by Agilent Microarray Scanner. All steps
were performed according to the manufacturer (Agilent Tech-
nologies, Palo Alto, CA) manuals. By this approach, we ana-
lyzed 45.033 transcripts in ×4 replicates both in resistant and
parental cells either siRNA transfected or not.
Validation steps for selected miRNAs and mRNAs
by real-time qRT-PCR
Following genome-wide microRNA andmRNA array results’
evaluation and comparison, we detected that twomiRNAs and
three mRNAswere significantly regulated due to siRNA treat-
ment among resistant and parental cells. Thus, we validated
these expressional changes via qRT-PCR in LightCycler 480.
miRNA validation
For miRNA validation, 16 total RNA samples (5 ng/μl
amount; totally 25 ng) were reverse transcribed into cDNA
by Universal cDNA synthesis kit (Exiqon, Vedbaek Den-
mark). In each cDNA synthesis reaction, also cDNA’s control
was achieved by using synthetic RNA spike-in primers. For
qRT-PCR, the obtained cDNAs were 1:80 diluted with
nuclease-free water; Snord48 and U6were used as housekeep-
ing genes. MicroRNA LNA™ primer sets for hsa-miR-
1245b-3p and hsa-miR-2278 (Exiqon, Vedbaek Denmark) in
cooperation with ExiLENT SYBR® Green Master Mix kit
(Exiqon, Vedbaek Denmark) were used in LightCycler 480
II instrument. After PCR, relative quantification of miRNAs
were done by Δ/ΔCt method and the obtained Ct values or
target miRNAs were normalized with housekeeping genes’ Ct
values. Thus, microRNA array results were checked once and
validated.
mRNA validation
For mRNA validation, all 16 total RNA samples (5 ng/μl
amount; totally 55 ng) were reverse transcribed into cDNA
by Transcriptor First Strand cDNA Synthesis Kit (Roche, Ap-
plied Science, Mannheim, Germany). In qRT-PCRwhile UPL
probes designed for AKT2, STAM, and STAT5A serve as
target genes, GAPDH was used as housekeeping gene, in
use with LightCycler® 480 Probes Master (Roche, Applied
Science, Mannheim, Germany) mix by LightCycler 480 II
instrument. The used probes are given in Table 1. Relative
quantification of target mRNAs was determined by the same
way given above; thus, the mRNA array results were checked
and validated.
Transient transfection of miRNA oligonucleotides
The miRNA mimic or inhibitor sequences specific to hsa-
miR-1245b-3p and hsa-miR-2278 and also anti-miR miRNA
inhibitor (negative control) [all purchased from Ambion
(Carlsbad, USA)] were transfected onto cells by HiPerFect
Transfection Reagent (Qiagen, Valencia, CA, USA) user man-
ual for a period of 72 h. miRNA transfected cells were used in
miRNA expression assay by qRT-PCR, western blot, poten-
tially regulated mRNAs’ expression analyses by qRT-PCR,
cell proliferation, and apoptosis assays.
Cell viability and proliferation assay
Cell proliferation assay was performed after transfection of
hsa-miR-2278 mimic or hsa-miR-2278 inhibitor. For this pur-
pose, after 72 h of miRNA transfection, 30×104 cells were
seeded in 96-well plates, and then, by applying increasing
doses of imatinib, cells were incubated for an additional
24 h. Cell viability was determined by using the WST-1 kit
(Roche Applied Science, Mannheim, Germany) and absor-
bance of each sample was measured spectrophotometrically
at 450 nmwith an ELISA reader (Thermo, Vantaa, Finland) in
triplicates.
Statistical analyses
The obtained microRNA array and mRNA array images after
scanning were analyzed by Agilent Feature Extraction soft-
ware in order to acquire signals and quality control reports.
After passing quality step, the quantile normalization was
done via GeneSpring GX (Agilent) 13.0 software. In conclu-
sion, expressional differences within groups were evaluated
by Moderated t test and Bonferroni family wise error rate
(FWER) for correction and >2 or more fold regulation was
accepted as significant with p value ≤0.05.
Relative mRNA expression levels gained at the end of
qRT-PCR analyses following siRNA treatments, miRNA
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expression profiles, and apoptosis assay results were evaluat-
ed with Student’s t test referring to significance of p≤0.05 in
GraphPad Prism software.
Results
Targeting STAT5A resulted in expressional
downregulation and induced apoptosis
The efficacy of siRNA transfection was determined by evalu-
ating suppression rates of STAT5A at mRNA and protein
levels by RT-qPCR and western blot analysis, respectively.
As shown in Fig. 1a, after anti-STAT5A-Chl modified siRNA
transfection, STAT5A mRNA expression levels were sup-
pressed by 80.28 % (−5.02-fold; p=0.0015) and 91.04 %
(−11.16-fold; p<0.0001) in K562 and K562/IMA-3 cells, re-
spectively. In accordance with mRNA suppression, also
STAT5A protein levels were inhibited due to siRNA treatment
in both parental and resistant cells compared to their
untransfected counterparts (Fig. 1b).
Next, we determined apoptosis rates following siRNA
treatment in both of the cells and indicated that apoptotic cell
number was significantly arisen in siRNA transfected cells as
compared to their untransfected control cells. As given in
Fig. 1c, while K562+ siRNA treated parental group exhibited
a 2.2-fold increase (p< 0.0001) compared to K562
untransfected cells, and 3.08-fold induction (p=0.001) was
detected in K562/IMA-3+ siRNA treated group compared to
untransfected K562/IMA-3 cells.
hsa-miR-2278 and hsa-miR-1245b-3p were emphasized
due to miRNome array: twinkle to regain of imatinib
response
We analyzed differing genome-wide microRNA expression
profiles in K562 and K562/IMA-3 cells, whereas miRNome
array results indicated that two miRNAs were significantly
regulated among cells due to STAT5A silencing. Since we
have generated four groups of cells as K562 UT, K562+
siRNA, K562/IMA-3 UT, and K562/IMA-3+ siRNA, we
initially focused on to determine the miRNA that exhibited
the highest expressional difference among parental and resis-
tant cells referred as BK562 UT^ and BK562/IMA-3 UT.^
Secondarily, we checked how expression of that miRNA
was regulated following siRNA treatment.
We detected that hsa-miR-2278 exhibited the lowest ex-
pression pattern in K562/IMA-3 UT cells as 0.028-fold nega-
tive regulation (p=0.047) that stand for a 35.7-fold downreg-
ulation compared to K562 UT cells. When we re-checked its
expression following siRNA treatment, we detected that it was
1.59-fold (p=0.065) positively regulated in BK562/IMA-3+
siRNA^ cells compared to BK562+ siRNA^ that stand for a
56.7-fold upregulation as the initial expression pattern of
0.028 (Supplementary material 1). But a more dramatic ex-
pressional change was detected when a comparison was done
among K562/IMA-3+ siRNA and K562/IMA-3UTcells: hsa-
miR-2278 expression was 10.23-fold positively regulated (p=
0.034) in K562/IMA-3+ siRNA cells that indicated a 365.3-
fold increase as compared to the initial expression pattern of
0.028. This expressional regulation following anti-STAT5A-
siRNA treatment indicated that resistant cells mimicked sen-
sitive cell expression pattern for hsa-miR-2278.
The maximally expressed one hsa-miR-1245b-3p among
resistant and parental cells also showed just the opposite effect
following gene silencing, and its expression was 7.14-fold
downregulated compared to untransfected resistant cells. So,
hsa-miR-1245b-3p expression was also converged to parental
cells due to STAT5A silencing with 146-fold downregulation
as its initial expression (Supplementary material 1).
Another important point is the need for validation of these
expressional changes once again via qRT-PCR since they were
detected by chip system. So, next, we re-quantitated expression
patterns of hsa-miR-2278 and hsa-miR-1245b-3p. Similar re-
sults were detected for miRNA expression profiles. While hsa-
miR-2278 was 0.068-fold negatively regulated (p=0.029) in
K562/IMA-3 UT compared to K562 UT cells in means of
14.7-fold downregulation in resistant untreated cell (Fig. 2a);
when anti-STAT5A-siRNAwas transfected, the expression was
10.02-fold positively regulated (p<0.0001) in K562/IMA-3+
siRNA cells compared to K562/IMA-3 UTcells (Fig. 2b). This
means that, following siRNA treatment in resistant cells, hsa-
miR-2278 expression was upregulated compared to its initial
expression and exhibited more similar expression pattern as in
parental untransfected cells.
For hsa-miR-1245b-3p validation analyses, similar results
were obtained. While 20.8-fold upregulation (p<0.0001) was
detected in K562/IMA-3 cells compared to parental cells
(Fig. 2c), when anti-STAT5A-siRNAwas transfected, the ex-
pression was 18.07-fold negatively regulated (p<0.0001) in
K562/IMA-3+ siRNA cells compared to K562/IMA-3 UT
cells (Fig. 2d).
All these data pointed out that silencing STAT5A had to-
tally changed expression patterns of hsa-miR-2278 and hsa-
Table 1 The probe sequences used in mRNA expression confirmation
analysis in LightCyler 480 II by qRT-PCR
STAM2; UPL#74 60 bp
F; GCATCCGGCACATTCTGTA
R; GGAGAGCTGCAATTGTTGG
STAT5A; UPL#110 64 bp
F; GCATCCGGCACATTCTGTA
R; GGAGAGCTGCAATTGTTGG
AKT2; UPL#158 72 bp
F; GTGTTAACAAAACCTCTACCTGTAACC
R; TTCTGGATAATGTATTTCAAACAGGA
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miR-1245b-3p in resistant cells, whereas resistant cells started
to exhibit similar expression pattern as sensitive cells which
might have important clinical reflection such as regain of
nilotinib response.
Genome-wide mRNA array results: combined analysis
in regard of detecting hsa-miR-2278
and hsa-miR-1245b-3p regulated genes
We used genome-wide mRNA array results for two outcomes.
First, we aimed to determine the differing expression patterns
among parental and resistant cells before and after siRNA
treatment. We detected some critical data in comparison be-
tween K562/IMA-3+ siRNA cells and K562/IMA-3 UTcells.
As for the array results, MDM2 oncogene expression was
3.76-fold significantly upregulated (p=0.014) in resistant
untransfected cells which meant that silencing STAT5A had
led to expressional downregulation in resistant cells. Another
promising result was seen in RAS protein activator like 1
(GAP1 like) (RASAL1), as 3.42-fold significant increase
(p=0.0039) in resistant untransfected cells compared to their
siRNA transfected outcomes. Also, STAT5A expression
levels were decreased in both siRNA transfected groups, with
4.34-fold (p=0.0021) and 2.8-fold (p=0.032) inhibitions in
K562/IMA-3+ siRNA and K562+ siRNA cells, respectively,
compared to their untransfected counterparts (Supplementary
material 2).
Secondarily and more importantly, we used these whole-
genome mRNA array data after determining potential target
mRNAs for either hsa-miR-2278 or hsa-miR-1245b-3p in
Fig. 1 Targeting STAT5A
resulted in expressional
downregulation and induced
apoptosis: a STAT5A mRNA
expression levels were
downregulated by 5.02-fold and
11.16-fold in K562 and K562/
IMA-3 cells, respectively
(*p=0.0015, **p<0.0001). b The
level of STAT5A protein
expression was decreased by
siRNA transfection in both K562
and K562/IMA-3 cells. Beta-actin
was used as loading control,
#SM1811, Fermentas Protein
marker was used in gels. c
Apoptosis induction was detected
in both siRNA treated cells with
2.2-fold in K562+ siRNA
parental group and 3.08-fold in
K562/IMA-3+ siRNA resistant
group compared to their
untransfected counterparts
(*p<0.0001, **p=0.001)
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correlation with miRTar in silico analyses and to prove the
interaction between them with further functional analyses.
But in miRTar-based interaction search, no potential regula-
tion was detected between either hsa-miR-2278:MDM2 or
hsa-miR-2278:RASAL1 and hsa-miR-1245b-3p:MDM2 or
hsa-miR-1245b-3p: RASAL1 except STAT5A.
At this point, we focused on the genes that were found in
JAK/STAT pathway as STAT5A being a member of this path-
way and our previous experiences with this cascade in CML.
After determining potential target genes by in silico analyses,
we checked their expression profiles once from whole-
genome mRNA array and proceeded with further analyses as
given below to prove the interactions.
Searching for potential targets of hsa-miR-2278
and hsa-miR-1245b-3p: STAT5A, AKT2, and STAM2 axis
of interaction for hsa-miR-2278
In further analyses, we explored the target genes that hsa-miR-
2278 and hsa-miR-1245b-3p might regulate; thus, we exam-
ined the predicted targets of these miRNAs using the miRTar
and TargetScan in silico algorithms. The analysis predicted
that there are complementary sites that recognize the seed
region of hsa-miR-2278 on 23 genes’ (AKT2, CBL, CCND2,
CCND3, CSF2, CSH1, GH1, GH2, IFNAR1, IL2RB, IL15RA,
LEPR, OSM, PIM1, PIK3R1, STAM2, STAT2, STAT5A,
STAT6, TPO, PIAS2, IL22RA2, IL28RA) mRNA 3′UTR from
the JAK/STAT pathway, whereas miR-1245b-3p exhibited
none. Among them, STAT5A, AKT2 (v-akt murine thymoma
viral oncogene homolog 2), and STAM2 (signal transducing
adaptor molecule) were selected for also taking place in the
whole-genome mRNA array obtained data. We selected
STAT5A as being the key player of the study, AKT2 for being
an oncogene and STAM2 as being a signal transducer of the
pathway. Functional analyses were carried out in order to con-
firm regulation between hsa-miR-2278 and STAT5A, AKT2
and STAM2 axis, and also to figure out the possible interac-
tion of these genes for miR-1245b-3p.
At this point, before ongoing with transient transfection of
miRNA oligonucleotides onto cells in order to confirm the
potential regulation between them, we checked STAT5A,
AKT2, and STAM2 mRNA expression values from the
whole-genome mRNA array data. We detected that both of
the mRNA expressions were downregulated by 4.34-fold (p=
0.0021), 3.78-fold (p=0.037), and 3.42-fold (p=0.043), re-
spectively, following siRNA treatment in resistant cells com-
pared to their untransfected counterparts (Supplementary
material 2).
Next, we validated these genes’ expressions by qRT-PCR
in order to confirm whole-genome mRNA array result. We
observed similar results and detected that while STAT5A
was 3.41-fold (p<0.0001) decreased, AKT2 was 3.15-fold
(p<0.0001) and STAM2 was 2.98-fold (p=0.0002) downreg-
ulated in siRNA treated resistant cells compared to
Fig. 2 Validation results by qRT-PCR for hsa-miR-2278 and hsa-miR-
1245b-3p expressional changes due to siRNA applications obtained from
miRNA array. a hsa-miR-2278 expression was 14.8-fold upregulated in
K562 parental cells compared to K562/IMA-3 resistant cells (p=0.029).
b anti-STAT5A-siRNA treatment changed hsa-miR-2278 expression
pattern in resistant cells, and its expression was 10.02-fold upregulated
(p<0.0001) compared to its untransfected counterpart. c hsa-miR-1245b-
3p expression was 20.8-fold upregulated (p<0.0001) in K562/IMA-3
cells compared to parental K562 cells. d Following anti-STAT5A-
siRNA treatment, hsa-miR-1245b-3p expression was 18.07-fold down-
regulated (p<0.0001) in K562/IMA-3 cells compared to its untransfected
counterpart
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untransfected resistant cells (Fig. 3) in re-quantification of
genes via real-time qRT-PCR in LightCycler 480.
By this approach, we acquired a beneficial clue and sup-
portive primary data that hsa-miR-2278 might be a tumor
suppressor before ongoing with miRNA transfection. Since
its expression was dramatically downregulated in resistant
cells, the critical intervention as STAT5A gene silencing in-
creased its expression, and this upregulation triggered the cells
to display as sensitive cell expression pattern which led us to
speculate that it could be a tumor suppressor at the early stages
of the study.
Effects of miRNA oligonucleotide transfections
upon imatinib resistance
Transfection efficiency control
Prior to studying the effects of hsa-miR-2278 and hsa-1245b-
3p, we used mimic or inhibitor miRNAs in order to check
transfection efficiency before ongoing with further experi-
ments. While expression levels of hsa-miR-2278 and hsa-
miR-1245b-3p were significantly increased by 13.1-fold
(p<0.0001) and 2.92-fold (p<0.0001), their expressions were
decreased by 3.11-fold (p<0.0001) and 2.75-fold (p=0.0001,)
respectively, following transfection either with mimic or in-
hibitor miRNAs, respectively (Fig. 4a, b), suggesting that the
oligonucleotides were efficiently transfected onto cells and
thus enhanced or repressed the expression of miRNAs.
Effects of miRNA transfection upon cell viability
and proliferation
Initially, we analyzed cell proliferation difference between pa-
rental and resistant cells due to imatinib treatment and detect-
ed that cell viability was reduced in a dose-dependent manner.
While IC50 dose of imatinib was calculated as 282 nM for
K562 parental cells, it was calculated as 12.54 μM for
K562/IMA-3 resistant cells (Fig. 5a). Next, we investigated
the effects of hsa-miR-2278 and hsa-miR-1245b-3p mimic or
inhibitor transfection upon viability and proliferation of leu-
kemia cells; we detected that upregulation in the expression
level of hsa-miR-2278 in resistant cells induced inhibition of
leukemic cell proliferation, which in turn reduced IC50 dose to
3.62 μM, and the average cell viability was reduced to 7.12±
0.66 % in 20 μM imatinib treated resistant cells compared to
NC inhibitor miRNA treated resistant cells (Fig. 5b). After
anti-miR-1245b-3p transfection, IC50 dose of imatinib was
reduced to 5.51 μM and the average cell viability was de-
creased to 14.21±0.79 % in 20 μM imatinib treated resistant
cells compared to NC inhibitor miRNA treated resistant cells
(Fig. 5c).
Taken together, these results indicated that especially pre-
miR-2278 transfection and to a lesser content anti-miR-
1245b-3p transfection increased sensitivity to imatinib in re-
sistant cells. While pre-miR-2278 transfected resistant cells
became 3.46 times more sensitive to imatinib, and anti-miR-
1245b-3p transfection exhibited 2.28-fold increased sensitivi-
ty compared to their NC inhibitor miRNA transfected
counterparts.
Increased expression levels of hsa-miR-2278 resulted
in induced leukemic cell apoptosis
As demonstrated in Fig. 6, while apoptosis rate was 5.06-fold
upregulated (p<0.0001) in pre-miR-2278 transfected resistant
cells compared to untreated resistant cells, anti-miR-1245b-3p
transfection triggered 1.92-fold induced apoptosis (p=0.002)
compared to untreated group in resistant cells. These findings
suggested that apoptosis induction of imatinib resistant cells
was significantly enhanced especially via upregulating hsa-
miR-2278 expression, which in turn resulted in regain of che-
motherapeutic response.
AKT2, STAM2, and STAT5A are functional targets
of hsa-miR-2278
At the last stage of the study, we aimed to determine the
possible interaction of STAT5A, AKT2, and STAM2 mRNAs
Fig. 3 Validation results by qRT-PCR for STAT5A, AKT2, and STAM2
mRNA expressional changes due to siRNA applications obtained from
mRNA array: While STAT5A expression was 3.41-fold (**p<0.0001)
decreased, AKT2 expression was 3.15-fold (*p<0.0001) downregulated
and STAM2 expression was 2.98-fold (***p=0.0002) downregulated in
siRNA treated K562/IMA-3 resistant cells compared to untransfected
K562/IMA-3 resistant cells after quantification of mRNAs by real-time
qRT-PCR in LightCycler 480
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between either with hsa-miR-2278 or hsa-miR-1245b-3p with
functional analysis. At the early stages of the study, we have
detected that the following anti-STAT5A-siRNA treatment
STAT5A, AKT2, and STAM2 mRNA expression levels were
downregulated in chip format and these results were validated
via qRT-PCR. Then, we had aimed to gain similar effects as
siRNA treatment with significantly differing miRNAs as hsa-
miR-2278 and hsa-miR-1245b-3p either by applying mimic
or inhibitor oligonucleotides.
Initially, we determined differing expression profiles of
these target mRNAs between parental and resistant cells by
qRT-PCR. As given in Fig. 7a, we detected that each mRNA
expression exhibited a higher expression pattern in K562/
IMA-3 cells compared to parental cells. While AKT2 expres-
sion was 1.87-fold higher, STAM2 and STAT5A mRNA ex-
pressions were 1.76-fold and 3.10-fold upregulated in resis-
tant cells, p<0.0001 for each. Next, we analyzed their expres-
sional changes following miRNA transfections. We observed
that while pre-miR-2278 transfected resistant cells triggered
1.89-fold expression downregulation in AKT2 mRNA ex-
pression in resistant cells compared to NC inhibitor miRNA
transfected cells, STAM2 was 1.81-fold and STAT5A expres-
sion was 4.78-fold downregulated (p<0.0001 for each),
whereas anti-miR-2278 exhibited no significant effect
(Fig. 7b). We made similar analyses for hsa-miR-1245b-3p
and did not observe significant differences neither mimic nor
inhibitor transfections for STAT5A, AKT2, and STAM2
mRNA expression profiles in resistant cells (Fig. 7c).
Next, we checked these potential target mRNAs’ varying
translational expression due to miRNA transfections by west-
ern blot analysis. The obtained results were in the same line
with mRNA results. While pre-miR-2278 oligonucleotide
transfection efficiently downregulated AKT2, STAM2, and
STAT5A protein expressions, miR-1245b-3p mimic or inhib-
itor transfection did not affect their protein expression levels
(Fig. 7d).
These results indicated that STAT5A, AKT2, and STAM2
were not regulated by hsa-miR-1245b-3p. Already, no inter-
action was reported between hsa-miR-1245b-3p and these
mRNAs by in silico analyses, but we had preferred to proceed
with further analyses in case there could be. But we detected
that STAT5A, AKT2, and STAM2 mRNAs were regulated by
hsa-miR-2278, and this miRNA was probably a tumor sup-
pressor thus upregulating its expression resulted in inhibition
in transcriptional and translational downregulation in its po-
tential target genes.
Discussion
In this study, we have selected the headliner as STAT5A since
we have experienced before that STAT5A exhibited major
effects upon the molecular basis of hematological malignan-
cies and gain of imatinib resistance; thus, targeting STAT5A
had remarkable clinical benefit as regain of chemotherapeutic
response and induced leukemic cell apoptosis especially in
imatinib resistant cells [11]. Based upon our previous studies,
in this current study, STAT5A was the main focus of our in-
terest and our selected target. Similar to us, Wang H et al. also
reported that upregulated activation of JAK/STAT signaling
pathway had promoted proliferation of leukemic cells in
CML, whereas STATs were therapeutic targets then [14].
We analyzed genome-wide microRNA and mRNA expres-
sion patterns as 2042 mature miRNAs frommiRBase ver:19.0
and 45.033 transcripts in parental K562 and imatinib resistant
K562/IMA-3 cells before and after silencing of STAT5A by
siRNA applications. As for the obtained results following
miRNome array, we detected that 273 miRNA expressions
were significantly upregulated ranging between 1047.86-fold
and 2.35-fold, whereas 131miRNAswere significantly down-
regulated between −2.56-fold and −35.7-fold in resistant cells
compared to sensitive cells. We detected that among them,
while hsa-miR-1245b-3p exhibited the highest expression,
hsa-miR-2278 showed the lowest expression in resistant cells
compared to parental cells. In literature search, till now, there
are no published papers related with hsa-miR-1245b-3p that
Fig. 4 The expression levels of hsa-miR-2278 and hsa-miR-1245b-3p
following mimic or inhibitor treatment: a While hsa-miR-2278
expression was increased by 13.1-fold (*p<0.0001), it was decreased
by 3.11-fold (**p<0.0001) following mimic and inhibitor miRNA
transfections, respectively. b While hsa-miR-1245b-3p expression was
2.92-fold upregulated (p<0.0 001), it was decreased by 2.75-fold (p=
0.0001) following transfection either with mimic or inhibitor, respectively
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stands for the maximally expressed miRNA in our imatinib
resistant cells. Whereas only one paper for hsa-miR-2278
could be found, which was in a totally different topic as a
SNP analyses (rs28366) for IL22RA2 and to define whether
hsa-miR-2278 binding affinity was significantly affected by
this SNP [15].
But there are some recently published papers in regard to
investigating miRNome transcriptome in hematologic cancers
as chronic myeloid leukemia [16–18]. Among them, in Bhutra
et al.’ s study, genome-wide miRNA expressions were pro-
filed in K562 cells following imatinib treatment, and miR-
493-5p was reported as the most significantly regulated
miRNA among treated and untreated control cells with 1.52-
fold upregulation in its expression due to imatinib treatment.
We have also a result for miR-493-5p, and similar to their
Fig. 5 Effects of miRNA transfection upon cell viability and
proliferation: a Differing IC50 doses of imatinib in K562/IMA-3 resistant
and K562 parental cells; calculated as 12.54 μM and 282 nM, respec-
tively. b pre-miR-2278 transfection inhibited resistant leukemic cell
proliferation in a dose-dependent manner and IC50 value was re-
calculated as 3.62 μM (left side) and cell viability was reduced to
7.12±0.66 with 20 μM imatinib treatment (right side). c anti-miR-
1245b-3p transfection triggered a lesser leukemic cell proliferation in-
hibition, whereas IC50 value of imatinib was reduced to 5.51 μM (left
side) and cell viability was reduced to 14.21±0.79 % with 20 μM
imatinib treatment (right side)
Fig. 6 Increased expression levels of hsa-miR-2278 resulted in induced
leukemic cell apoptosis: While pre-miR-2278 transfection triggered 5.06-
fold upregulated (*p<0.0001) apoptosis induction, anti-miR-1245b-3p
transfection induced 1.92-fold increased (**p=0.002) apoptosis in resis-
tant cells both compared to control cells
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Fig. 7 AKT2, STAM2, and
STAT5A are functional targets of
hsa-miR-2278: a Differing
expression patterns of STAT5A,
AKT2, and STAM2 mRNAs
between K562/IMA-3 resistant
and parental cells. While AKT2
expression was 1.87-fold higher,
STAM2 and STAT5A mRNA
expressions were 1.76-fold and
3.10-fold upregulated in resistant
cells, *,**,***p<0.0001 for each.
b AKT2, STAM2, and STAT5A
mRNA expression levels in
K562/IMA-3 resistant cells after
miRNA transfection was re-
quantitated by qRT-PCR. While
expressional down regulations
were detected by pre-miR-2278,
increases were observed
following anti-miR-2278
treatment for each mRNA
compared to NC inhibitor treated
group (p<0.0001 for all). c anti-
miR-1245b-3p transfection did
not cause any significant
expressional changes in mRNA
profiles regarding AKT2,
STAM2, and STAT5A are not
potential targets of has-miR-
1245b-3p. d The level of AKT2,
STAM2, and STAT5A protein
expression levels was decreased
following pre-miR-2278
transfection, whereas anti-miR-
1245b-3p did not affect any. Beta-
actin was used as loading control,
#SM1811, Fermentas Protein
marker was used in gels
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reports, we have detected that it was 3.54-fold upregulated in
imatinib resistant cells compared to parental cells.
Based upon the enlargement of analyzed patterns, our
study seems to be the first one that handled genome-wide
screening as for both miRNA and mRNA, in point of silenc-
ing STAT5A, thus comparing imatinib sensitive and resistant
cells which stands for the superiority of our study. Following
siRNA treatments, we detected that hsa-miR-2278 expression
was significantly upregulated in its untransfected counterpart
resistant cells. So, the minimal expression pattern was 365.3-
fold increased following silencing STAT5A, and the gained
expression profile was similar to sensitive parental cells,
which led us to conclude that resistant cells exhibited sensitive
cells’ expression pattern. Similar expressional differentiation
due to siRNA treatment was observed in hsa-miR-1245b-3p,
and its expression was more likely to parental cells afterwards.
After performing validation steps for these expressional
changes with qRT-PCR analyses, we continued with function-
al analyses in order to define regulation between these
miRNAs and their potential target mRNAs. Due to whole-
genome mRNA array data and using in silico algorithms, we
detected that STAT5A, AKT2, and STAM2 from JAK/STAT
pathway were potential target mRNAs for has-miR-2278 by
applying mimic transfection specific to hsa-miR-2278. The
obtained results from qRT-PCR assay and western blot anal-
yses indicated that while pre-miR-2278 transfection led ex-
pressional decreases in STAT5A, AKT2, and STAM2 mRNA
and protein expression levels that normally exhibit increased
expression profiles in CML pathogenesis [19]. Thus, we pre-
dicted that hsa-miR-2278 was probably a tumor suppressor
while its upregulated expression had therapeutic effect upon
resistant cells. But no interaction was reported for hsa-miR-
1245b-3p and these selected mRNAs, and we also did not find
any at the end of miRNA transfections and functional analy-
ses. But downregulation in miR-1245b-3p expression exhib-
ited some promising results as sensitizing cells to imatinib by
1.66-fold and inducing apoptosis 1.92-fold in resistant cells,
so we speculated that miR-1245b-3p displayed these naive
therapeutic responses by targeting some other mRNAs.
Also, we checked miRNA transfection effect upon cell
viability and proliferation and detected that leukemic cell pro-
liferation was dramatically reduced following pre-miR-2278
transfection in resistant K562/IMA-3 cells. At the final stage
of the study, we checked apoptotic case of the cells following
miRNA treatments and observed that leukemic cell apoptosis
was induced significantly as 5.06-fold in resistant cells.
Overall, uniqueness of our study is handling imatinib resis-
tance phenomenon in much different points of molecular ap-
proaches. But there are some reported papers regarding
miRNA expressional differences among parental and imatinib
resistant cells like our study. In 2012, Turrini E et al. published
a paper in the means of discovering the facts about imatinib
resistance by comprising 667 miRNAs in array system in
parental and low-dose imatinib resistant (4 months of imatinib
treatment) K562 cells. They reported interaction between
miR-212 and miR-328 with ABCG2 [20].
A more recent study was reported by Li Y et al. in 2013,
and they used RNAi approach for selective inhibition of BCR-
ABL expression and then monitored miR-203 expressional
changes among parental and imatinib resistant BaF3-BCR-
ABL cells. Overexpression of miR-203 inhibited cell growth
and colony formation ability of leukemic cells, whereas
targeting BCR-ABL expression by siRNA in correlation with
miR-203 mimic transfection restored the sensitivity to imatin-
ib in cells expressing the imatinib resistant BCR-ABL kinase
domain mutant T315I [21]. Similar to our aim, these two
reported studies also put forward the molecular basis of ima-
tinib resistance in the means of miRNA profiling approach
combined with siRNA applications.
Our investigations have disclosed the importance of JAK/
STAT pathway member STAT5A in gain of resistance to che-
motherapeutic agent imatinib and how silencing resulted in
gain of response. Besides STAT5A, also STAT3 has signifi-
cant roles in hematological malignancies as we and others also
have reported before [22, 23]. Similar to our inferences about
the significance of JAK/STAT pathway members—especially
STAT family, Rozovski U et al. reported that STAT3 regulated
microRNA gene expression in chronic lymphocytic leukemia
cells and presence of activated STAT3 had a profound effect
on miRNA expression in CLL cells [24]. In another very
recently published study, suppressing miR-155 expression
through JAK/STAT pathway member STAT3 exhibited a ther-
apeutic approach by promoting human acute myelogenous
leukemia cell model HL60 cells’ differentiation in accompany
of leukemia inhibitory factor receptor α-chain (LIFRα-CT3)
and its TAT fusion protein [25]. All these data exhibit the
efficacy of targeting STAT family member-based hematolog-
ical cancer therapies.
In conclusion, we put a milestone in discovering the mo-
lecular basis of gained imatinib resistance due to silencing
STAT5A and by monitoring miRNome and transcriptome as-
says; we highlighted hsa-miR-2278 as a tumor suppressor.
Thus, upregulating hsa-miR-2278 expressionmight be a func-
tional therapeutic approach in order to have clinical benefit
and gain of drug response in CML therapy for inhibiting leu-
kemic cell proliferation and inducing apoptosis. In the future,
it will be beneficial to analyze differing expression profiles in
both CML responder and imatinib-resistant patients.
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